text: **Day 2 tests: private provider requirements**
  
  **7.**—(1) For the purposes of paragraph 6(1)(b)(iii), a private provider complies with this 
  
  paragraph where— 
  
  (a) they comply with the requirements of paragraph 3(1)(a) and (e) to (h) of Schedule 10 as if 
  any reference in those provisions to an appropriate test were a reference to a day 2 test; 
  (b) if the provider is a laboratory that conducts diagnostic test evaluation for testing in 
  accordance with this Schedule, they have made a declaration to the Department of Health 
  and Social Care that they meet the minimum standards for private sector-provided testing 
  at https://support-covid-19-testing.dhsc.gov.uk/InternationalTesting; 
  
  (c) they have provided the Department of Health and Social Care with a list of all 
  organisations that they work with (whether by sub-contract or otherwise) to carry out the 
  testing service or to carry out genomic sequencing, indicating the nature of the service 
  that each organisation is providing, and kept that list updated as appropriate; 
  
  (d) the person responsible for the taking of samples meets the relevant requirements for 
  accreditation to ISO standard 15189 or ISO/IEC standard 17025 in respect of the taking 
  of samples; 
  
  (e) the laboratory used by the test provider for the processing of samples meets the relevant 
  requirements for ISO standard 15189 or ISO/IEC standard 17025 in respect of the 
  evaluation of the established molecular detection method and the genomic sequencing of 
  samples; 
  
  (f) 
  
  they receive the information required by paragraph 10(3) or (4) (as appropriate), and if 
  they administer the test to P, they do so no later than the end of the second day after the 
  day on which P arrived in England; 
  
  (g) each day, they notify the Secretary of State in writing of— 
  (i) the number of tests they sold on that day, and 
  (ii) in relation to each test sold on that day— 
  
  (aa) 
  the date of the arrival in England of the person in respect of whom the test 
  was sold, and 
  
  (bb) whether the person in respect of whom the test was sold is a category 1 arrival 
  
  or not; 
  
  (h) they sequence each sample with a cycle threshold less than 30 (equivalent to ~1,000 viral 
  genome copies per millilitre); 
  
  (i) 
  
  in respect of the sequencing of samples, they must secure a reference genome coverage 
  breadth of at least 50% and at least 30 times coverage; 